Giorgio Saladino

Giorgio Saladino

Auto-generated profile, based on publicly available information

Giorgio Saladino

Department of Chemistry, University College London, London, United Kingdom

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 February 2016 in Chemical Reviews
Verified
Journal Article
Closed access
EPElena Papaleo
Elena Papaleo
GSGiorgio Saladino
Giorgio Saladino
MLMatteo Lambrughi
Matteo Lambrughi
KLKresten Lindorff-Larsen
Kresten Lindorff-Larsen
FGFrancesco Luigi Gervasio
Francesco Luigi Gervasio
RNRuth Nussinov
Ruth Nussinov

20 October 2016 in Journal of the American Chemical Society
Verified
Journal Article
Open access
VOVladimiras Oleinikovas
Vladimiras Oleinikovas
GSGiorgio Saladino
Giorgio Saladino
BCBenjamin P. Cossins
Benjamin P. Cossins
FGFrancesco Luigi Gervasio
Francesco Luigi Gervasio
Cryptic pockets, that is, sites on protein targets that only become apparent when drugs bind, provide a promising alternative to classical binding sites for drug development. Here, we investigate the nature and dynamical properties of cryptic sites in four pharmacologically relevant targets, while comparing the efficacy of various simulation-based approaches in discovering them. We find that the studied cryptic sites do not correspond to local minima in the computed conformational free energy landscape of the unliganded proteins. They thus promptly close in all of the molecular dynamics simulations performed, irrespective of the force-field used. Temperature-based enhanced sampling approaches, such as Parallel Tempering, do not improve the situation, as the entropic term does not help in the opening of the sites. The use of fragment probes helps, as in long simulations occasionally it leads to the opening and binding to the cryptic sites. Our observed mechanism of cryptic site formation is suggestive of an interplay between two classical mechanisms: induced-fit and conformational selection. Employing this insight, we developed a novel Hamiltonian Replica Exchange-based method “SWISH” (Sampling Water Interfaces through Scaled Hamiltonians), which combined with probes resulted in a promising general approach for cryptic site discovery. We also addressed the issue of “false-positives” and propose a simple approach to distinguish them from druggable cryptic pockets. Our simulations, whose cumulative sampling time was more than 200 μs, help in clarifying the molecular mechanism of pocket formation, providing a solid basis for the choice of an efficient computational method.

12 December 2014 in Accounts of Chemical Research
Verified
Journal Article
Closed access
ACAndrea Cavalli
Andrea Cavalli
ASAndrea Spitaleri
Andrea Spitaleri
GSGiorgio Saladino
Giorgio Saladino
FGFrancesco Luigi Gervasio
Francesco Luigi Gervasio

1 April 2013 in Cancer Cell
Verified
Journal Article
Closed access
CHCorentin Herbert
Corentin Herbert
USUlrich Schieborr
Ulrich Schieborr
KSKrishna Saxena
Krishna Saxena
JJJarek Juraszek
Jarek Juraszek
Frederik De SmetFrederik De Smet
Frederik De Smet
FBFrançoise Bono
Françoise Bono

25 November 2015 in PLOS Computational Biology
Verified
Journal Article
Open access
PDF file
SLSilvia Lovera
Silvia Lovera
MMMaria Morando
Maria Morando
EPEncarna Pucheta-Martinez
Encarna Pucheta-Martinez
JMJorge Luis Martinez-Torrecuadrada
Jorge Luis Martinez-Torrecuadrada
GSGiorgio Saladino
Giorgio Saladino
FGFrancesco Luigi Gervasio
Francesco Luigi Gervasio
Due to its inhibition of the Abl kinase domain in the BCR-ABL fusion protein, imatinib is strikingly effective in the initial stage of chronic myeloid leukemia with more than 90% of the patients showing complete remission. However, as in the case of most targeted anti-cancer therapies, the emergence of drug resistance is a serious concern. Several drug-resistant mutations affecting the catalytic domain of Abl and other tyrosine kinases are now known. But, despite their importance and the adverse effect that they have on the prognosis of the cancer patients harboring them, the molecular mechanism of these mutations is still debated. Here by using long molecular dynamics simulations and large-scale free energy calculations complemented by in vitro mutagenesis and microcalorimetry experiments, we model the effect of several widespread drug-resistant mutations of Abl. By comparing the conformational free energy landscape of the mutants with those of the wild-type tyrosine kinases we clarify their mode of action. It involves significant and complex changes in the inactive-to-active dynamics and entropy/enthalpy balance of two functional elements: the activation-loop and the conserved DFG motif. What is more the T315I gatekeeper mutant has a significant impact on the binding mechanism itself and on the binding kinetics. Imatinib remains the most important and studied anti-cancer drug for cancer therapy in its new paradigm. Due to its inhibition of the Abl kinase domain, imatinib is strikingly effective in the initial stage of chronic myeloid leukemia with more than 90% of the patients showing a complete remission. However, the emergence of drug resistance is a serious concern. Here, we investigate the molecular mechanism of drug-resistant mutations which, despite the importance and the adverse effect on cancer patients prognosis, is still debated. Our extensive molecular simulations and free energy calculations are consistent with an allosteric effect of the single-point drug-resistance-causing mutations on the conformational dynamics. Two partially independent conformational changes play a role. Our findings might help the design of anti-cancer therapies to overcome drug resistance and be used to predict the clinical relevance of new drug-resistant mutants found by genetic screenings of tumor samples.

1 October 2016 in Cell Chemical Biology
Verified
Journal Article
Closed access
JSJörg O. Schulze
Jörg O. Schulze
GSGiorgio Saladino
Giorgio Saladino
KBKatrien Busschots
Katrien Busschots
SNSonja Neimanis
Sonja Neimanis
ESEvelyn Süß
Evelyn Süß
RBRicardo M. Biondi
Ricardo M. Biondi